比较局部晚期宫颈癌的全球治疗指南以优化最佳实践:一项系统性与范围综述
该综述系统比较了1999年1月至2021年8月间发布的46部来自31个国家、地区和国际组织的局部晚期宫颈癌指南。多数指南推荐影像学用于诊断和分期,对IIB至IVA期首选顺铂为基础的同步放化疗有全球共识,而IB2至IIA2期的治疗推荐存在差异。指南差异可能与所用分期标准、资源可及性和预防规划效果有关。
要点
- 46部指南中41部使用分期标准,其中27部使用2009 FIGO分期。
- IIB至IVA期首选顺铂为基础的同步放化疗获全球共识,仅少数例外。
- IB2至IIA2期的治疗推荐在各指南间存在差异。
核心结论
- 局部晚期宫颈癌各分期治疗指南的差异可能受所用分期标准、资源可及性和预防规划效果影响。
- 解决这些方面可能统一指南并改善全球结局,随着新疗法出现,指南的审查与更新将很重要。
研究设计与样本
- 系统文献综述与针对性检索,纳入1999年1月至2021年8月间发表的宫颈癌治疗指南。
- 指南通过文献数据库、卫生技术评估数据库、疾病专门网站和卫生组织网站识别,针对性检索包括宫颈癌高患病率或高死亡率地区的国家指南。
- 非英文指南由母语者或在线翻译服务翻译,最终比较了来自31个国家、地区和国际组织的46部指南。
主要发现
- 46部指南中41部使用分期标准,其中27部使用2009 FIGO分期。
- 多数指南推荐影像学检查用于诊断和分期,胸部X线、静脉肾盂造影、CT和MRI常用于诊断和分期,MRI和PET-CT推荐用于评估淋巴结状态和远处转移,且PET-CT优先于MRI。
- IIB至IVA期首选顺铂为基础的同步放化疗获全球共识,仅少数例外;IB2至IIA2期的治疗推荐各异。
- 多数指南同意根治性子宫切除术后高复发风险者行辅助同步放化疗、中复发风险者行辅助放疗,其他辅助和新辅助治疗推荐各异。
关键数值与推荐
- 46部指南中41部使用分期标准,其中27部使用2009 FIGO分期。
- IIB至IVA期首选顺铂为基础的同步放化疗获全球共识,仅少数例外。
- 根治性子宫切除术后高复发风险者辅助同步放化疗、中复发风险者辅助放疗获多数指南同意。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival outcomes for cervical cancer differ between countries and world regions. Locally advanced cervical cancer (LACC) is associated with poorer outcomes than early-stage disease. Country-specific variations in diagnostic and treatment recommendations might contribute to differences in LACC outcomes among countries. OBJECTIVE: We compared international and country-specific guidelines for LACC diagnostic imaging and treatment recommendations. METHODS: A systematic literature review and targeted search were used to identify cervical cancer treatment guidelines published between January 1999-August 2021. Guidelines were identified via literature databases, health technology assessment databases, disease-specific websites, and health organization websites. The targeted search included guidelines from countries in regions known to have high cervical cancer prevalence or mortality. Non-English guidelines were translated by native speakers or online translation services. RESULTS: Forty-six guidelines from 31 countries, regions, and international organizations were compared (41/46 using staging criteria, 27 of which used 2009 FIGO). Most guidelines recommended imaging tests for diagnosis and staging. Chest X-ray, intravenous pyelogram, CT, and MRI were commonly recommended for diagnosis and staging while MRI and PET-CT were recommended for the assessment of lymph node status and distant metastases, with a preference for PET-CT over MRI. There was global consensus for cisplatin-based concurrent chemoradiation as primary treatment for stages IIB to IVA, with few exceptions. Treatment recommendations for stages IB2 to IIA2 varied. Most guidelines agreed on adjuvant concurrent chemoradiation after radical hysterectomy when there is a high recurrence risk, and adjuvant radiotherapy when there is an intermediate recurrence risk. Recommendations for other adjuvant and neoadjuvant therapies varied among the guidelines. CONCLUSIONS: Differences among treatment guidelines by LACC stage might be influenced by staging criteria used, resource availability, and prevention program effectiveness. Addressing these areas may unify guidelines and improve global outcomes. Review and update of guidelines will be important as novel LACC therapies become available.
引用
- Pujade-Lauraine E, Tan DSP, Leary A, et al. Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review. Gynecol Oncol. 2022. PMID: 36096973. doi:10.1016/j.ygyno.2022.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。